Royalty Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO Royalty Pharma is Pablo Legorreta, benoemd in Jan1996, heeft een ambtstermijn van 28.83 jaar. bezit rechtstreeks 0.82% van de aandelen van het bedrijf, ter waarde $ 133.78M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 4.4 jaar.

Belangrijke informatie

Pablo Legorreta

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	28.8yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Apr 04

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Analyse CEO-vergoeding

Hoe is Pablo Legorreta's beloning veranderd ten opzichte van Royalty Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$673m
Mar 31 2024	n/a	n/a	US$799m
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	n/a	n/a	US$184m
Jun 30 2023	n/a	n/a	US$255m
Mar 31 2023	n/a	n/a	US$332m
Dec 31 2022	n/a	n/a	US$43m
Sep 30 2022	n/a	n/a	US$507m
Jun 30 2022	n/a	n/a	US$466m
Mar 31 2022	n/a	n/a	US$602m
Dec 31 2021	US$50m	US$8m	US$620m
Sep 30 2021	n/a	n/a	US$783m
Jun 30 2021	n/a	n/a	US$972m
Mar 31 2021	n/a	n/a	US$493m
Dec 31 2020	US$56m	n/a	US$495m
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$29m	n/a	US$2b

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Pablo redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: De vergoeding van Pablo is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Pablo Legorreta (60 yo)

28.8yrs

Tenure

Mr. Pablo Gerardo Legorreta serves as Chairman of the Board at ProKidney Corp. He is a Co-Founder & Director of Sequel Med Tech, LLC. He serves as the Chief Executive Officer and Co-Founder at RP Managemen...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Pablo Legorreta	Founder	28.8yrs	geen gegevens	0.82% $ 133.8m
Terrance Coyne	Executive VP & CFO	no data	US$4.56m	0.19% $ 30.6m
George Lloyd	Executive VP of Investments & Chief Legal Officer	2.1yrs	US$4.56m	0.24% $ 39.3m
Christopher Hite	Vice Chairman & Executive VP	4.6yrs	US$4.56m	0.083% $ 13.5m
Marshall Urist	Executive Vice President of Research & Investments	3.9yrs	US$4.56m	0.015% $ 2.4m
Arthur McGivern	Executive Vice President of Investments & General Counsel	2.1yrs	geen gegevens	geen gegevens
Ashwin Pai	Executive Vice President of Investments	1.6yrs	geen gegevens	geen gegevens
Kristin Stafford	Senior VP & Chief Accounting Officer	no data	geen gegevens	geen gegevens
Eric Schneider	Senior VP & Chief Technology Officer	1.2yrs	geen gegevens	geen gegevens
James Reddoch	Executive VP of Investments & Chief Scientific Officer	3.9yrs	US$3.40m	geen gegevens
George Grofik	Senior VP and Head of Investor Relations & Communications	no data	geen gegevens	geen gegevens
Molly Sawaya	Executive VP & Head of Human Capital	less than a year	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RPRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Pablo Legorreta	Founder	28.8yrs	geen gegevens	0.82% $ 133.8m
David Hodgson	Independent Director	2.4yrs	US$389.77k	0.0037% $ 598.2k
Ted Love	Independent Director	4.3yrs	US$389.77k	0.0082% $ 1.3m
Errol De Souza	Independent Director	4.4yrs	US$389.77k	0.014% $ 2.4m
Henry Fernandez	Lead Independent Director	4.3yrs	US$389.77k	0.023% $ 3.8m
Gregory Norden	Independent Director	4.4yrs	US$389.77k	0.014% $ 2.4m
Bonnie Bassler	Independent Director	4.4yrs	US$389.77k	0.011% $ 1.8m
Catherine Engelbert	Independent Director	4.4yrs	US$389.77k	0.0076% $ 1.2m

4.4yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RPRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Royalty Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Recent updates

Price target decreased by 7.7% to US$41.43

Royalty Pharma plc to Report Q3, 2024 Results on Nov 06, 2024

Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Second quarter dividend of US$0.21 announced

Royalty Pharma Declares Fourth Quarter 2024 Dividend, Payable on December 10, 2024

Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Consensus EPS estimates fall by 33%

Royalty Pharma: Busy Putting Capital To Work

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of US$0.21 per share

Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

First quarter dividend of US$0.21 announced

Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024

Royalty Pharma plc Declares Dividend for the Third Quarter of 2024, Payable on September 13, 2024

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)

Upcoming dividend of US$0.21 per share

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Fourth quarter dividend of US$0.21 announced

Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 79%

Royalty Pharma: Solid Operational Performance

Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)

Upcoming dividend of US$0.21 per share at 2.9% yield

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Consensus EPS estimates increase by 68%

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Consensus EPS estimates increase by 94%

Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)

Upcoming dividend of US$0.20 per share at 2.9% yield

Consensus EPS estimates increase by 55%

Consensus EPS estimates increase by 15%

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Founder recently bought US$3.8m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Insider recently sold US$6.5m worth of stock

Insider notifies of intention to sell stock

Director notifies of intention to sell stock

Founder recently bought US$7.7m worth of stock

Consensus EPS estimates increase by 243%

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of US$0.20 per share at 2.4% yield